Vosoritide
Vosoritide is an FDA-approved C-type natriuretic peptide analog. Achondroplasia is caused by gain-of-function variants in FGFR3 that over-activate the MAPK pathway and suppress chondrocyte proliferation at the growth plate. Vosoritide binds natriuretic peptide receptor B, raising cyclic GMP and inhibiting MAPK signalling downstream of FGFR3, which relieves that suppression.
For research use only.
Key Facts
- CAS
- 1480724-61-5
- Molecular Weight (MW)
- 4103 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Analog of C-type natriuretic peptide approved to increase linear growth in children with achondroplasia who have open epiphyses.
Peptide Library's Vosoritide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C176H290N56O51S3 |
|---|---|
| Molecular weight | 4103 g/mol |
| CAS number | 1480724-61-5 |
| PubChem CID | 119058036 |
| FDA UNII | 7SE5582Q2P |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Achondroplasia is caused by gain-of-function variants in FGFR3 that over-activate the MAPK pathway and suppress chondrocyte proliferation at the growth plate. Vosoritide binds natriuretic peptide receptor B, raising cyclic GMP and inhibiting MAPK signalling downstream of FGFR3, which relieves that suppression. Its modified N-terminus resists neutral endopeptidase degradation, giving a longer half-life than native CNP.
Studies
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial
- Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence
Regulatory & research status
Vosoritide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Vosoritide: frequently asked questions
What is Vosoritide?
Analog of C-type natriuretic peptide approved to increase linear growth in children with achondroplasia who have open epiphyses.
How does Vosoritide work?
Achondroplasia is caused by gain-of-function variants in FGFR3 that over-activate the MAPK pathway and suppress chondrocyte proliferation at the growth plate. Vosoritide binds natriuretic peptide receptor B, raising cyclic GMP and inhibiting MAPK signalling downstream of FGFR3, which relieves that suppression.
Is Vosoritide FDA approved?
Yes. Vosoritide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Vosoritide?
Compounds most often compared with Vosoritide include Human Growth Hormone (Somatropin), Lanreotide, Lonapegsomatropin and Macimorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study — Med, 2025External reference
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial — Lancet Child Adolesc Health, 2024External reference
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study — Genet Med, 2021External reference
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial — Lancet, 2020External reference
- Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence — Cureus, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Vosoritide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Vosoritide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →